

## Prostatype Genomics receives declarations of intent to exercise warrants of series TO 4 of approximately 37%

**Prostatype Genomics AB ("Prostatype Genomics" or the "Company") has received declarations of intent to exercise warrants of series TO 4 (the "Warrants") from a number of major holders of Warrants. The declarations of intent encompass approximately 37 percent of the total number of Warrants, corresponding to approximately SEK 3.7 million**

Prostatype Genomics has received declarations of intent from members of the board of directors and other major shareholders regarding the exercise of Warrants. The declarations of intent encompass approximately 618 million Warrants, corresponding to approximately 37 percent of the total number of Warrants.

"It is encouraging to receive such strong indications from major shareholders at an early stage in the subscription period", says Anders Lundberg, chairman of the board, who intends to exercise all his TO 4 warrants for subscription of shares.

CEO Fredrik Rickman agrees: "After having submitted our application to be approved for reimbursement by Medicare in the US market, we are now close to initiate the next phase in the Company's history: focused sales efforts in the world's largest market for our product category. These indications show a strong declaration of trust from major shareholders in our ability to successfully embark on this journey", he says.

The Warrants have an exercise period from November 25, 2024, up to and including December 9, 2024, and a thousand (1,000) warrants of series TO 4 grant the right to subscribe for one (1) new share. The subscription price for TO 4 has been set at 5.96 SEK per share, corresponding to 70 percent of the volume-weighted average price (VWAP) of the Company's share during the period 11 to 22 November 2024. If all warrants of series TO 4 are fully exercised, the Company will receive approximately 9.9 million SEK before issuance costs.

To note, if the warrants are owned through an investments savings account (Sw. *ISK*) or an endowment insurance (Sw. *Kapitalförsäkring*), warrant holders should contact their nominee well in advance for further instructions regarding the exercise of Warrants, as different nominees have different processing times.

Complete terms and instructions for warrants of series TO 4 well as an information folder containing summary information about the warrant exercise on Prostatype Genomics' ([www.prostatypegenomics.com](http://www.prostatypegenomics.com)) and Nordic Issuing AB's ([www.nordic-issuing.se](http://www.nordic-issuing.se)) respective websites during the exercise period.

A webpage that continuously collects information about the TO 4 exercise period can be accessed via this link: <https://www.ii.se/en/progen-to4-2024-eng/>

**Important dates**

- 5 December 2024: Last day of trading in TO 4.
- 9 December 2024: Exercise period ends.
- 10 December 2024: Preliminary date for announcement of outcome of the exercise.
- 20 December 2024: Preliminary date for conversion from interim shares to ordinary shares.

**Advisors**

In connection with the warrant exercise, Prostatype has engaged Gemstone Capital A/S as financial advisor, Advokatfirman Lindahl KB as legal advisor and Nordic Issuing AB as issuing agent.

**For further information about Prostatype Genomics, please contact:**

Fredrik Rickman, CEO Prostatype Genomics AB

Telephone: +46 (0) 73 049 77 01

Email: [fredrik.persson@prostatypegenomics.com](mailto:fredrik.persson@prostatypegenomics.com)

**About Prostatype Genomics AB**

Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

**Important Information**

This press release does not constitute an offer to acquire, subscribe for, or otherwise trade in shares, warrants, unit rights, BTUs, or other securities in Prostatype Genomics AB. Investors should not subscribe for or acquire any securities other than on the basis of the information in the prospectus published prior to the commencement of the subscription period in the Rights Issue. No action has been or will be taken to allow a public offering in any jurisdictions other than Sweden.

This press release may not be released, published, or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, the United Kingdom, South Africa, South Korea, Russia, Belarus, or any other jurisdiction where the distribution of this press release would be unlawful. This press release does not constitute an offer to sell new shares, warrants, subscription rights, BTUs, or other securities to any person in a jurisdiction where such an offer would be unlawful or would require prospectuses, additional registration, or other measures beyond those required by Swedish law. The prospectus and other documents related to the Rights Issue may not be distributed in or into any country where such distribution or the Rights Issue requires actions as mentioned above or where it would conflict with the regulations of such country. Any actions in violation of these instructions may constitute a breach of applicable securities laws.

No shares, warrants, unit rights, BTUs, or other securities have been or will be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under the securities laws of any state or other jurisdiction of the United States, and may not be offered, subscribed for, exercised, pledged, sold, resold, allotted, delivered, or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction of the United States.

This press release may contain certain forward-looking statements reflecting the Company's current views on future events as well as financial and operational developments. Words such as "intends," "assesses," "expects," "may," "plans," "believes," "estimates," and other expressions indicating or predicting future developments or trends and that are not based on historical facts constitute forward-looking statements. Forward-looking statements are, by nature, associated with both known and unknown risks and uncertainties, as they depend on future events and circumstances. Forward-looking statements do not constitute a guarantee of future results or developments, and actual outcomes may differ materially from what is expressed in the forward-looking statements. Neither the Company nor any other party undertakes to review, update, confirm, or publicly announce any revisions of any forward-looking statements to reflect events that occur or circumstances that arise with regard to the content of this press release, unless required by law or the Nasdaq First North Growth Market's regulations.

*This information is information that Prostatype Genomics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-11-26 15:10 CET.*